Adjuvant T-DM1 Approved in Europe for HER2+ Early Breast Cancer

The European Commission has approved ado-trastuzumab emtansine for the adjuvant treatment of adult patients with HER2-positive early breast cancer who have residual invasive disease (breast and/or lymph nodes) following neoadjuvant taxane-based chemotherapy and HER2-targeted therapy.

Read the full article here

Related Articles